Experimental cocktail aims to tackle tough lymphoma
NCT ID NCT04049825
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tested an experimental drug called OPB-111077 combined with two standard chemotherapy drugs (bendamustine and rituximab) in 36 people whose diffuse large B-cell lymphoma had come back or stopped responding to treatment. The main goal was to check the safety and find the right dose, not to measure how well it works. The study is already completed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OPB-111077 (an experimental drug) combined with bendamustine and rituximab (standard chemotherapies)
What this could lead to
If successful, this could point toward a new combination treatment option for people with relapsed or refractory diffuse large B-cell lymphoma.
What could go wrong
This is a very early (Phase 1) trial with only 36 participants, focused on safety and dosing. It is not designed to prove effectiveness, and the combination may cause significant side effects or fail to work in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yamagata University Hospital
Yamagata, Japan